Miller Canfield (JD Supra India)

4 results for Miller Canfield (JD Supra India)

  • Visa Appointments Cancelled in India Due to COVID-19

    U.S. Embassy and Consulate posts throughout India announced today that in light of the global COVID-19 pandemic, all immigrant and nonimmigrant visa appointments scheduled on Monday, March 16, 2020, onward have been cancelled. Once the posts are able to resume regular consular operations, appointments will be made available and individuals will be able to reschedule.

  • Supreme Court of India Denies Novartis Patent Application

    In a landmark judgment delivered on April 1, 2013, the Supreme Court of India dismissed an appeal by Novartis AG, a Swiss pharmaceutical giant, to win patent protection in India for its cancer drug Glivec. The polarizing decision has been hailed by activists as a step in the right direction for affordable healthcare, and as being detrimental to innovation and investment by the international...

  • Arbitration Process Reconfirmed in Landmark Indian Supreme Court Decision

    On September 6, 2012, the Supreme Court of India delivered a landmark decision in Bharat Aluminium Co v Kaiser Aluminium Technical Services Inc. In a decision that is expected to be welcomed by the international arbitration community, a five-judge constitutional bench of the court overruled Bhatia International v Bulk Trading S.A. and restricted the ability of Indian courts to interfere in...

  • Compulsory License Granted to Indian Pharmaceutical Company

    On March 12, 2012, India’s Patent Office approved an application by Natco Pharma Limited for a compulsory license to sell a generic version of Bayer AG’s kidney and liver cancer drug Nexavar. In 2008, Bayer had filed and was granted a patent on the drug. Also, Bayer had refused to grant a voluntary license to NATCO previously. This is the first time that an Indian company has

  • Request a trial to view additional results

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT